(Q41438984)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

0 references

Jennifer L Meyers

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Taralyn E Rogers

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Randy L Fast

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Anthony D Bassett

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Patricia L Worsham

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Bradford S Powell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Sarah L Norris

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Arthur M Krieg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

13 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

2220-2229

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

Yersinia pestis (plague) vaccines

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Toll-like receptor signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Vaccine adjuvant formulation: a relatively neglected field that is crucial to vaccine success

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Interleukin-12 induces a Th1-like response to Burkholderia mallei and limited protection in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Lymphokine control of in vivo immunoglobulin isotype selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Safety of CpG oligodeoxynucleotides in veterinary species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Use of CpG oligodeoxynucleotides as immunoprotective agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Therapeutic potential of Toll-like receptor 9 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CpG DNA induces stronger immune responses with less toxicity than other adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CpG oligodeoxynucleotides as vaccine adjuvants in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Use of CpG oligodeoxynucleotides as immune adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

A hypervariable N-terminal region of Yersinia LcrV determines Toll-like receptor 2-mediated IL-10 induction and mouse virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

The weak interaction of LcrV and TLR2 does not contribute to the virulence of Yersinia pestis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Tolls and beyond--many roads to vaccine immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Cooperation of Toll-like receptor signals in innate immune defence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

The fraction 1 and V protein antigens of Yersinia pestis activate dendritic cells to induce primary T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.016

10.1016/J.VACCINE.2009.02.016

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19428836%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference